Sveinn Sölvason, President and CEO, comments:
"Sales in Q4 2024 amounted to USD 225 million. Organic sales growth was 5% for the quarter and local currency growth was 8%. The continued strong momentum we have seen throughout the year in our Prosthetics & Neuro Orthotics business continued to drive our growth, supported by good growth contribution across all our regions.

For the full year 2024, our organic sales growth was 6%, driven by a strong performance in EMEA and our Prosthetics & Neuro Orthotics and Patient Care segments. Our profitability continues to be strong with an EBITDA margin before special items of 21% for Q4 and 20% for 2024. Lastly, we also saw strong cash flow generated for the quarter with USD 34 million or equivalent to 15% of sales."

Embla Medical will host a conference call on Feb 5, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST. A webcast can be followed by clicking the following link: Embla Medical full year results 2024 webcast

To participate in the telephone conference please use the dial-in details provided below:
DK: +45 78 76 84 90
SE: +46 31-311 50 03
UK: +44 20 3769 6819
US: +1 646 787 0157
Participant access code: 274982

Download Company Announcement
Download Investor Presentation
Download 2024 Annual Report
Visit 2024 Annual Report Site